Explore

Rapid Read Rapid Read
MIT-Led Study Develops Adjuvant to Enhance Mucosal Immunity in Polio Vaccines

MIT-Led Study Develops Adjuvant to Enhance Mucosal Immunity in Polio Vaccines

Researchers at the Massachusetts Institute of Technology have developed an experimental adjuvant that could enhance mucosal immunity when used with injectable polio vaccines. The adjuvant, Am80, is delivered using lipid nanoparticles, allowing for a slow release that stimulates immune cells to target the mucosal lining of the intestine. This approach aims to provide the benefits of the oral polio vaccine, which induces mucosal immunity, without its associated risks. Initial tests in rats have shown promising results, with increased production of antibodies necessary for mucosal immunity.
Rapid Read Rapid Read
MIT Researchers Develop Adjuvant to Enhance Injectable Polio Vaccine's Mucosal Immunity

MIT Researchers Develop Adjuvant to Enhance Injectable Polio Vaccine's Mucosal Immunity

Researchers at the Massachusetts Institute of Technology have developed a new adjuvant that could enhance the mucosal immunity of the injectable polio vaccine. The injectable form of the polio vaccine is effective at preventing illness but does not block virus transmission as effectively as the oral version. The oral vaccine induces a mucosal immune response in the gastrointestinal tract, which is the primary site of virus exposure. However, due to a small risk of infection, several countries have stopped using the oral vaccine. The new adjuvant, known as Am80, is delivered with a lipid nanoparticle that releases it slowly, allowing for a sustained immune response. This approach aims to combine the safety of the injectable vaccine with the mucosal immunity benefits of the oral vaccine, potentially aiding in polio eradication efforts.
Trendline Trendline
Advancements in mRNA Therapeutics Highlight Potential for Disease Treatment

Advancements in mRNA Therapeutics Highlight Potential for Disease Treatment

Advancements in mRNA Therapeutics Highlight Potential for Disease Treatment
Rapid Read Rapid Read
Ebola Vaccine Candidates Fast-Tracked to Combat Rare Strain in Central Africa

Ebola Vaccine Candidates Fast-Tracked to Combat Rare Strain in Central Africa

Three vaccine candidates are being expedited to address the Ebola outbreak caused by the Bundibugyo species in Central Africa. The Coalition for Epidemic Preparedness Innovations (CEPI) is investing over $60 million in three vaccine developers, while Gavi, another vaccine nonprofit, plans to spend $40 million to purchase these vaccines once approved. The candidates include an IAVI-developed vaccine similar to the approved Ervebo, a University of Oxford vaccine using the Oxford-AstraZeneca COVID-19 approach, and an mRNA vaccine from Moderna. Despite the financial backing, it may take several months before these vaccines are available for public use due to manufacturing and testing requirements.
Rapid Read Rapid Read
CEPI and Gavi Fund Development of Ebola Vaccine for Bundibugyo Strain Amid DRC Outbreak

CEPI and Gavi Fund Development of Ebola Vaccine for Bundibugyo Strain Amid DRC Outbreak

The Coalition for Epidemic Preparedness Innovation (CEPI) and Gavi, a global vaccine alliance, have committed over $100 million to fast-track the development of vaccines targeting the Bundibugyo strain of Ebola, which is currently driving a significant outbreak in the Democratic Republic of Congo (DRC). Three vaccine candidates are being developed by IAVI, the University of Oxford, and Moderna. IAVI's candidate, which uses a vesicular stomatitis virus to deliver immune instructions, is the most advanced in testing. Despite the funding, it will take months to determine the vaccines' efficacy and even longer for widespread use. The urgency of the situation is underscored by the outbreak's scale, which is one of the largest on record.
Rapid Read Rapid Read
Public Health Agencies Use Biosecurity to Promote Vaccine Development Amid Rare Virus Threats

Public Health Agencies Use Biosecurity to Promote Vaccine Development Amid Rare Virus Threats

Dr. Peter McCullough, Chief Scientific Officer at The Wellness Company, discussed the role of public health agencies in promoting vaccines through biosecurity measures on Real America’s Voice. He highlighted how these agencies, in coordination with mainstream media, create a sense of fear around rare viruses like hantavirus and Ebola, which pose minimal risk to the general public. McCullough argued that this fear is used to prepare the market for future vaccines, suggesting that the pharmaceutical industry benefits from this strategy. He noted that while hantavirus and Ebola are serious diseases, they are not easily transmitted in community settings, and the focus on vaccines overlooks practical prevention measures. McCullough also mentioned ongoing research into hantavirus vaccines, which have not yet been approved in the U.S. or Europe.
Rapid Read Rapid Read
NASA Study Reveals Jupiter's Role in Earth's Elemental Composition

NASA Study Reveals Jupiter's Role in Earth's Elemental Composition

NASA-supported scientists have unveiled new insights into how Earth may have acquired essential elements for life, highlighting Jupiter's influence in the process. The study, published in Science Advances, examines the phosphorus to nitrogen ratio in meteorites, suggesting that Earth obtained these elements primarily from the inner solar system. Jupiter's formation and gravitational influence played a crucial role in restricting the movement of these elements, leading to a higher phosphorus to nitrogen ratio in the inner solar system. This discovery challenges previous theories that outer solar system chondrites significantly contributed to Earth's elemental inventory.
Rapid Read Rapid Read
Harvard Study Finds Flu Vaccine Prevents Up to 14 Cases Per 100 Children

Harvard Study Finds Flu Vaccine Prevents Up to 14 Cases Per 100 Children

A study conducted by researchers at Harvard Medical School has found that the childhood influenza vaccine can prevent between 9 and 14 cases of flu per 100 children vaccinated. The study, published in JAMA Pediatrics, analyzed insurance claims for children aged two to five years over five flu seasons from 2016 to 2023, excluding the 2020/2021 and 2021/2022 seasons due to COVID-19. The research highlighted that children with autumn birthdays had higher vaccination rates and lower influenza diagnosis rates compared to those with summer birthdays. The study was released on June 1, 2026, coinciding with discussions by the Company Chemists’ Association (CCA) on the role of community pharmacies in delivering childhood vaccinations. Nick Thayer, head of policy at the CCA, emphasized the capacity of pharmacies to administer vaccines, particularly in underserved communities, and mentioned plans for pharmacies to deliver catch-up HPV vaccines.
Rapid Read Rapid Read
Researchers Develop Promising Hantavirus Treatments Amid Funding Challenges

Researchers Develop Promising Hantavirus Treatments Amid Funding Challenges

Researchers in Chile, Argentina, and the United States are making progress in developing treatments and vaccines for hantavirus, a rare but deadly virus transmitted by rodents. Despite the virus being known for decades, limited funding has hindered the development of effective treatments. Recent outbreaks, such as one on a cruise ship, have highlighted the need for medical solutions. A study published recently suggests that a drug used for autoimmune diseases may help mitigate severe symptoms of hantavirus. The Andes virus, a strain capable of human-to-human transmission, is a particular focus due to its high mortality rate. Efforts are also underway to develop vaccines and antibody treatments, although these face significant financial and logistical hurdles.
Rapid Read Rapid Read
Cross-Reactive T Cells Offer Hope for Broad Vaccines Against Measles and Nipah Virus

Cross-Reactive T Cells Offer Hope for Broad Vaccines Against Measles and Nipah Virus

Researchers at the La Jolla Institute for Immunology have discovered that cross-reactive T cells could be key in developing broad vaccines or treatments for paramyxoviruses, including measles and Nipah virus. The study, led by Alessandro Sette, PhD, mapped human CD4+ T cell epitopes across these viruses, revealing conserved regions that could trigger immune responses against multiple paramyxovirus species. This finding suggests that instead of targeting individual viruses, vaccines could be designed to activate these cross-reactive T cells, offering protection against a wider range of viruses within the family. The research highlights the potential for new vaccine strategies that leverage existing population immunity.
Rapid Read Rapid Read
POP Biotechnologies Receives $9.7 Million CEPI Funding for Vaccine Development

POP Biotechnologies Receives $9.7 Million CEPI Funding for Vaccine Development

POP Biotechnologies, a Buffalo-based biotech company, has secured up to $9.7 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance its SNAP nanoparticle vaccine platform into Phase 1 clinical trials. The funding will support the development of a vaccine candidate targeting H5N1 avian influenza, leveraging the SNAP platform's ability to enhance immune responses through protein-tagging technology. This investment builds on a previous $1.5 million award from CEPI, aimed at accelerating the development of vaccines against epidemic and pandemic threats.
Trendline Trendline
US Department of Energy Allocates $134 Million for Rare Earth Projects in Louisiana and Oklahoma

US Department of Energy Allocates $134 Million for Rare Earth Projects in Louisiana and Oklahoma

US Department of Energy Allocates $134 Million for Rare Earth Projects in Louisiana and Oklahoma